by EpicentRx | Jul 26, 2023 | Company Updates
As you may have noticed, EpicentRx is a company on the move. From the award of FDA Fast Track status for RRx-001 as an anti-oral mucositis agent to invited talks at premier venues like the AD/PD conference in Gothenburg, Sweden and the World Parkinson Congress in...
by EpicentRx | Jul 24, 2023 | Blog
“The meek shall inherit the… words of the week.” SNO Definition: Abbreviation: SNO stands for S-nitrosothiol. This is an organic compound that contains a nitroso (-NO) group attached to a sulfur. Example sentences: “Nibrozetone (RRx-001) releases a...
by EpicentRx | Jul 19, 2023 | Blog
As Shakespeare might have put it had he lived in 2023 amid the record-breaking heatwave that has gripped parts of Eastern Asia, Europe, and North America, “Now is the summer of our discontent”. Or, as Glenn Frye, founding member of the Eagles, famously voiced, “The...
by EpicentRx | Jul 19, 2023 | Blog
Cisplatin (cis-diamminedichloroplatinum) plus intensity-modulated radiation therapy, also called IMRT, is the mainstay of treatment for head and neck cancer (HNC). In a randomized Phase 2 trial called PREVLAR, the addition of nibrozetone (RRx-001) to chemoradiation...
by EpicentRx | Jul 18, 2023 | Blog
Necessity is the mother of invention, so the saying goes. Sometimes it is also the father. The father in this case is Dr. Tony Reid, previously the Primary Investigator (PI) on the first-in-human (FIH) clinical trial for nibrozetone (RRx-001) (see blog post entitled...
